A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. We deliver solutions designed to empower clinicians and improve patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics-based information for transplant patients. Our headquarters is located in Brisbane, California, and we have other primary operations in Omaha, Nebraska and Stockholm, Sweden. We were originally incorporated in Delaware in December 1998 under the name Hippocratic Engineering, Inc. In April 1999, we changed our name to BioCardia, Inc., and in June 2002, we changed our name to Expression Diagnostics, Inc. In July 2007, we changed our name to XDx, Inc.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 380M | 380M | 334M | 280M | 322M | 296M |
| Net Income | -21M | -21M | 53M | -190M | -77M | -31M |
| EPS | $-0.40 | $-0.40 | $0.93 | $-3.54 | $-1.44 | $-0.59 |
| Free Cash Flow | 36M | 36M | 32M | -27M | -46M | -33M |
| ROIC | -9.4% | -6.3% | 28.9% | -72.8% | -17.8% | -6.6% |
| Gross Margin | 45.5% | 45.5% | 78.9% | 79.4% | 77.5% | 76.0% |
| Debt/Equity | 0.06 | 0.06 | 0.06 | 0.11 | 0.08 | 0.04 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -31M | -31M | 41M | -203M | -77M | -30M |
| Operating Margin | -8.1% | -8.1% | 12.2% | -72.5% | -24.0% | -10.0% |
| ROE | -7.0% | -6.3% | 13.9% | -72.8% | -17.8% | -6.6% |
| Shares Outstanding | 53M | 53M | 57M | 54M | 53M | 52M |
CareDx, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 25.0x vs a median of 33.3x. The company's 5-year average gross margin is 71.5%. Total shareholder yield (buybacks) is 9.3%. At current prices, the estimated annualized return to fair value is +11.3%.
CareDx, Inc. (CDNA) has a 5-year average return on invested capital (ROIC) of -14.9%. This is below average and may indicate limited pricing power.
CareDx, Inc. (CDNA) has a market capitalization of $941M. It is classified as a small-cap stock.
CareDx, Inc. (CDNA) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 9.33%.
CareDx, Inc. (CDNA) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
CareDx, Inc. (CDNA) reported annual revenue of $380 million in its most recent fiscal year, based on SEC EDGAR filings.
CareDx, Inc. (CDNA) has a net profit margin of -5.6%. The company is currently unprofitable.
CareDx, Inc. (CDNA) generated $36 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CareDx, Inc. (CDNA) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
CareDx, Inc. (CDNA) reported earnings per share (EPS) of $-0.40 in its most recent fiscal year.
CareDx, Inc. (CDNA) has a return on equity (ROE) of -6.3%. A negative ROE may indicate losses or negative equity.
CareDx, Inc. (CDNA) has a 5-year average gross margin of 71.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for CareDx, Inc. (CDNA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CareDx, Inc. (CDNA) has a book value per share of $5.68, based on its most recent annual SEC filing.